Analyst Ratings for Mirum Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 6 analysts have published their opinion on Mirum Pharmaceuticals (NASDAQ:MIRM) stock, all of them being bullish. The average 12-month price target for the stock is $72.33, a decrease of 4.51% from the previous average price target of $75.75.
September 13, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts are bullish on Mirum Pharmaceuticals with a 12-month price target of $72.33, a decrease from the previous target.
The unanimous bullish sentiment from analysts indicates a positive outlook for Mirum Pharmaceuticals. However, the decrease in the average price target could suggest a potential slowdown in the stock's growth, which might impact its short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100